Background: Periodic ultrasonography (US) examination is recommended in many patients with papillary thyroid carcinoma (PTC) after treatment with radioactive iodine (RAI), but recurrences are confirmed in few cases. This study determined whether the indication of US in the first years after treatment with RAI can be selective when postoperative US and posttherapy whole-body scanning (RxWBS) ruled out persistent neck disease. Methods: This was a prospective study. Two hundred and fifty-four patients with PTC (242 of intermediate risk) undergoing thyroidectomy and RAI, who had no apparent disease at the time of initial therapy (including negative postoperative US and RxWBS), were studied. The patients were followed up for 5 years after treatment with RAI by annual US. Results: At the end of 5 years, 47 patients (18.5%) had at least one suspicious US, but neck recurrence was confirmed in only 4 patients (1.5% of all patients and 8.5% of those with suspicious US). The remaining cases were considered false-positives. US did not reveal disease in the first or second year after treatment with RAI in any patient. In the third, fourth, and fifth year after treatment with RAI, considering only patients with unstimulated Tg < 1 ng/ mL in these assessments, US revealed disease in 0, 1 (0.4%), and 1 (0.4%) patient, respectively. Conclusion: The results suggest that low-or intermediate-risk patients with PTC without persistent disease after thyroidectomy (including negative postoperative US and RxWBS) do not require repeat US examination in the first two years after treatment with RAI. In the following years until the fifth year, US can be restricted to patients with Tg ≥1 ng/mL.
Introduction
Ultrasonography (US) is a widely available, noninvasive, and sensitive technique for the detection of locoregional disease in patients operated on for papillary thyroid carcinoma (PTC). After ablation or adjuvant therapy with radioactive iodine (RAI), US should be obtained a few months later in all patients as part of the investigation that defines the response to therapy [1] [2] [3] . After this first assessment, the American Thyroid Association (ATA) DOI: 10.1159/000493978 [2] and the European Thyroid Association (ETA) [1] only exclude the need for repeat US in patients (i) of low risk, (ii) with excellent response to therapy, and (iii) with persistently negative unstimulated Tg (u-Tg) and anti-Tg antibodies (TgAb). Even in these cases, the recommendation of repeating US at least every 12-24 months within the first 5 years has recently been reiterated [3] . However, US frequently reveals "suspicious" lesions that raise patient concern and required fine-needle aspiration (FNA) but that are not malignant (false-positives) [4] . Furthermore, most patients with PTC (except high-risk patients) will not develop disease after treatment with RAI [2] . Consequently, the detection of a neck recurrence requires US to be performed in many patients as well as several examinations per patient [4] , sometimes followed by FNA, resulting in high costs.
In patients with macroscopically complete tumor resection who receive RAI, persistent locoregional disease is more commonly detected by posttherapy whole-body scanning (RxWBS) [5] . Recently, postoperative US (before RAI) has been shown to be a valuable procedure [1-3, 6, 7] , which can even detect lymph node metastases not apparent on RxWBS [6] [7] [8] . So far, few studies have routinely obtained postoperative US before RAI in a large number of patients [6, 7] . These studies were retrospective. Since it was already known that the patients would subsequently receive RAI, it is possible that US was less detailed, since the result would not change the decision on RAI administration, or that only lesions that were candidates for reoperation were reported. The time to obtain US after surgery was also not predefined or standardized. Finally, only one study reported the results of US after RAI in patients with negative postoperative US [6] .
The objective of this prospective study was to determine whether the indication of US could be selective in the first years after RAI when postoperative US and Rx-WBS ruled out persistent neck disease after total thyroidectomy.
Patients and Methods

Study
This was a prospective study. The study was approved by the local Research Ethics Committee, and the subjects gave informed consent.
Patients
The patients of this study were treated at our hospital between 2006 and 2014. During this period until today, patients with PTC have been evaluated routinely 3-4 months after surgery by US/ Doppler. For this study, patients submitted to total thyroidectomy who received RAI and who did not have persistent disease according to the criteria in Table 1 were selected. Patients with poorly differentiated carcinoma and extensive extrathyroid invasion (pT4) were excluded. In addition, to avoid underestimating recurrences, patients with classical PTC ≤4 cm restricted to the thyroid and without vascular invasion were not included. Patients with TgAb were also excluded. Once included in the study, the patients were followed up for 5 years after treatment with RAI as described below.
Ablation with RAI
The patients were submitted to ablation with RAI after levothyroxine withdrawal for 4 weeks or administration of recombinant human TSH and administration of a low-iodine diet for 10 days prior to the procedure. 30, 50, or 100 mCi was administered. Anterior and posterior whole-body images were obtained 7 days after RAI (RxWBS).
Initial Assessment after Treatment with RAI
The patients were evaluated 12 months after the administration of RAI by u-Tg and TgAb measurement and US.
Follow-Up
The patients were followed up by clinical examination, measurement of u-Tg and TgAb at intervals of 6-12 months, and annual US. The time of follow-up was 60 months in all patients.
Imaging Methods
US was performed with a linear, multifrequency, 14-MHz transducer for morphological analysis and for power Doppler evaluation. The absence of US abnormalities was defined when no lymph nodes with any of the following findings were detected: (i) microcalcification, (ii) cystic degeneration, (iii) peripheral hypervascularization, and (iv) absence of a hilum with a long axis/short axis ratio < 2 and no vascularized nodule in the thyroid bed [9, 10] . US/Doppler was performed by a radiologist experienced in thyroid imaging. All suspected lesions apparent on the scans were evaluated by US-guided FNA (cytology and Tg). True-positive US findings were defined based on the results of cytology, FNA-Tg, and histology. 
Results
Two hundred and fifty-four patients met the selection criteria ( One year after treatment with RAI, US was suspicious in 10 patients, but FNA (cytology and measurement of Tg in the needle washout) excluded the recurrence of a tumor, and these cases were, therefore, considered falsepositive US. In the second year, suspicious US with negative FNA was observed in an additional 8 patients. In the third year, lymph node recurrence was detected by US in one patient. This patient had u-Tg ≥1 ng/mL at the time of recurrence detection. Suspicious US with negative FNA was observed in an additional 9 patients. In the fourth year, US was suspicious in 10 further patients, but recurrence was confirmed in only two. One of the patients with recurrence detected by US had u-Tg < 1 ng/mL at diagnosis. Finally, in the fifth year after treatment with RAI, US revealed suspicious lesions in 9 further patients but recurrence was confirmed in only one. This patient had u-Tg < 1 ng/mL at the time of US.
At the end of 5 years, 47 patients (18.5%) had at least one suspicious US, but neck recurrence was confirmed in only 4 (1.5% of all patients and 8.5% of those with suspicious US). The remaining cases were considered falsepositives. Thus, in the absence of persistent neck disease (including no abnormal postoperative US findings and negative RxWBS), US did not reveal structural disease in the first or second year after treatment with RAI in any patient. In the third, fourth, and fifth year after treatment with RAI, considering only patients with u-Tg < 1 ng/mL in these assessments as has been proposed recently [4] , US revealed disease in 0, 1 (0.4%), and 1 (0.4%) patient, respectively. The two patients with recurrence on US and u-Tg < 1 ng/mL had detectable concentrations of this marker; thus, none of the patients with undetectable Tg and TgAb after treatment with RAI exhibited recurrence on US.
To avoid overestimation of the frequency of false-positive results, for the 47 patients who had at least one suspicious US, we considered the number of scans obtained until the first suspicious US. Thus, 1,176 scans were obtained; of these, 1,129 (96%) did not reveal suspicious lesions, only 4 (0.35%) resulted in the confirmation of recurrence, and 43 (3.65%) were considered false-positives. It should be noted that, over the period of 5 years, only two neck recurrences were detected by other imaging methods in the absence of corresponding lesions on US.
Discussion
This study evaluated patient with PTC since, different from follicular carcinoma, recurrences are mainly cervical in this histological type, and US plays, therefore, a more important role. Patients submitted to lobectomy were not included since periodic US seems to be essential for the follow-up of these patients due to the limitations of Tg and TgAb [1, 12, 13] and due to the need for evaluating not only lymph node metastases but also the remnant lobe [1] . Easily available information was used to define "the absence of persistent disease" after thyroidectomy. In fact, RxWBS has always been recommended after RAI therapy [2] and postoperative US (before RAI) is currently also indicated [1-3, 6, 7] . Finally, we restricted follow-up to the first 5 years after treatment with RAI, since most recurrences occur during this period [1, 14, 15] and periodic US examination is more commonly recommended during these years [1, 3] .
To the best of our knowledge, there is only one previous study in which postoperative US was obtained routinely in a significant number of patients; in this study, 16/468 patients (3.4%) with negative US and RxWBS showing no ectopic cervical uptake had recurrences on US scans obtained after treatment with RAI [6] . However, that study was retrospective, with the limitations inherent in its design, a considerable number of patients were high risk, and serum Tg at recurrence detection was not reported. In another recent study that proposes to restrict US to patients with u-Tg ≥1 ng/mL after treatment with RAI, this imaging method revealed disease in only 2.1% of all scans obtained in patients with u-Tg < 1 ng/mL [4] . That study was also retrospective, and postoperative US was not obtained; thus, patients with US abnormalities in this imaging method were not excluded as was done in the present study. In the absence of an apparent tumor in the neck after thyroidectomy, including US and RxWBS, repeat US examination in the first year after RAI, as recommended by current guidelines [1] [2] [3] , did not show disease in any of the 254 patients. The same was observed in the second year. In the subsequent three years, if US were restricted to patients with u-Tg ≥1 ng/mL [4] , 95% of the patients could be exempted from this examination, and the risk of tumor recurrence in the neck going undetected due to the omission of US would be only 0.4% in these patients. We attributed these results to the following facts. First, US was performed by an experienced professional, US was not obtained immediately after surgery, reducing the risk of artifacts that could compromise appropriate evaluation of the neck [1, 6, 8] , and we adopted a criterion to define "suspicious" US. As previously demonstrated by us, this criterion is highly sensitive [10] . We believe that this care can be applied in clinical practice without major difficulty. Second, in addition to US, RxWBS was also used to rule out persistent disease, and the application of this method after treatment with RAI is a well-established recommendation [2] . It should be noted that we did not perform SPECT/CT, as currently preferred [2, 16] , which could theoretically increase sensitivity and further improve the negative predictive value of initial assessment. We recognize that the results cannot be applied to high-risk patients. In contrast, the results can be extrapolated to low-risk patients submitted to total thyroidectomy without RAI. In this case, it is possible that the u-Tg cut-off excluding repeat US in these patients is > 1 ng/mL because of the presence of thyroid remnant.
As reported in other studies [4] , we demonstrate that US detected many more false-positives than true-positive recurrences. Among patients with at least one "suspicious" US, the disease was confirmed in only 8.5%. Considering only US scans performed at the currently recommended times after treatment with RAI, i.e., in the first year and repeated in the third and fifth year [1] [2] [3] , more than 750 scans were obtained for the detection of 4 recurrences, a fact that renders the detection of one recurrence expensive at least in these patients.
In conclusion, the results suggest that low-or intermediate-risk patients with PTC without persistent disease after total thyroidectomy (including postoperative US and RxWBS) do not require repeat US examination in the first two years after treatment with RAI. In the following years until the fifth year, this imaging method can be restricted to patients with u-Tg ≥1 ng/mL [4] and would not be necessary in patients with undetectable Tg and TgAb.
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